A batch of medicine hospitals cannot be sold (with list)

According to the Notice, the drugs suspended include azithromycin tablets, ibuprofen particles, ovine flat tablets, Malay acid inapuri tablets, hydrochloric acid bromine tablets, etc.
, Achimycin for the second batch of band procurement varieties, O nitrogen flat tablets, Malay acid Inapri tablets for the first batch of band procurement involved varieties.
, also in Jiangsu Province, on April 17th, the Jiangsu Provincial Public Resources Trading Center issued a notice to suspend the purchase of drugs that had not been evaluated consistently.
According to Cypress Blue combing, in this notice, Jiangsu Province suspended the procurement of 152 drugs - including amosicillin capsules, omeprazole intestinal capsules, oxalic acid aspirin tablets, meloxicon tablets, sodium bicarbonate tablets, cephalosporine capsules, left ethyl rahitan tablets, involving national medicine, medicine, Baiyunshan, Shisi, North China Pharmaceuticals and other pharmaceutical companies.
According to the Opinions on the Conduct of Consistent Evaluation of the Quality and Efficacy of Generic Drugs issued by the General Office of the State Council on March 5, 2016 (State Administration issued No. 8 of 2016), more than 3 production enterprises with the same varieties of drugs that have passed the consistent evaluation will no longer be selected for varieties that have not passed the consistent evaluation in the areas of centralized drug procurement.
According to Saibai Blue combing, for some time, Guangxi, Shanghai, Jiangsu, Beijing, Shenzhen, Liaoning and other more than 20 provinces for the non-consistent evaluation of drugs frequently issued a suspension of trading qualification notice - of which in a notice in Guangxi, the suspension of procurement of non-conformity evaluation drugs reached 708;
note that for some of the varieties that have not been evaluated consistently, Shanghai is more in a job tip, or stop procurement and health insurance settlement.
the normalization of procurement, consistent evaluation phase-out accelerated it is not difficult to see that many of the suspended procurement of non-consistent evaluation products, are and the national collection of varieties with the generic name of the drug.
analysis points out that according to the selection rules of centralized procurement of drugs organized by the state, the national collection of varieties is often concentrated in large enterprises, more over-evaluated manufacturers, market competition is more adequate and fierce.
Plus over-consistent evaluation of varieties manufacturers and even some of the original research products production enterprises significantly reduced prices, as well as related policies to ensure the use of selected drugs in the national collection of factors superimposed, in these varieties, for the un-evaluated manufacturers of the elimination effect is significant.
From the point of view of volume procurement, these manufacturers do not have the right to participate in volume procurement;
Up to now, in the national collection of varieties, has fully reflected the elimination effect of the policy - the first round of national collection covering 25 varieties, the second round of collection involving 32 varieties, just released the results of the third round of collection confirmed 55 varieties, pharmaceutical companies to be selected.
less than two years, these countries involved in the collection of varieties of unseeded, selected, un-evaluated enterprises, has ushered in a completely different fate trend, their development and differentiation is increasingly evident.
It should not be overlooked that, with the gradual normalization of strip procurement, at least for the current policy of clear consistency evaluation of chemical oral preparations and chemical injection-related varieties, as long as the number of enterprises over-consistent evaluation is sufficient, and the number of over-evaluated varieties accumulated to dozens, will automatically trigger national organizations to carry out volume procurement.
this trend, there is no doubt that more drugs will usher in the policy of elimination.
In addition, even if the normal pressure of strip procurement is removed, according to the State Drug Administration's Bulletin on the Evaluation of the Conformity of the Quality and Efficacy of Generic Drugs, generic drugs, since the first variety has passed the consistent evaluation, the same varieties of other pharmaceutical manufacturers should in principle complete the consistent evaluation within 3 years.
can be said that in the head generic drug companies in the race, if you still want to meet market access qualifications, a large number of small and medium-sized enterprises are still facing the pressure of consistent evaluation.
After all, on the popular varieties, moving hundreds of batches of the situation is not uncommon - take through the consistent evaluation of the enterprise's large number of varieties of metformin hydrochloride tablets, this variety through the consistent evaluation of pharmaceutical companies have been close to 30, but holding the domestic approval of metformin tablets more than 110 pharmaceutical companies.
that in the case of this variety, almost three-quarters of pharmaceutical companies have yet to pass a consistent evaluation.
it is not difficult to see that in the consistent evaluation of the policy requirements, there are the vast majority of pharmaceutical companies, may not be able to compete in this variety of market competition.
According to the statistics of the State Drug Administration, there are 165.699 million domestic drug approvals, of which nearly 150,000 are generic drug approvals, for most pharmaceutical companies that do not have the strength to do a consistent evaluation, they have a good chance will usher in the elimination of products.
the national collection of selected varieties, this phase-out effect reflects a more rapid and obvious.
.